Article Versions Notes

Formica V, Lucchetti J, Doldo E, Riondino S, Morelli C, Argirò R, Renzi N, Nitti D, Nardecchia A, Dell’Aquila E, et al. Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients—The Importance of Tissue/Plasma Discordant Cases. Journal of Clinical Medicine. 2021; 10(1):87. https://doi.org/10.3390/jcm10010087

Formica, Vincenzo, Jessica Lucchetti, Elena Doldo, Silvia Riondino, Cristina Morelli, Renato Argirò, Nicola Renzi, Daniele Nitti, Antonella Nardecchia, Emanuela Dell’Aquila, and et al. 2021. "Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients—The Importance of Tissue/Plasma Discordant Cases" Journal of Clinical Medicine 10, no. 1: 87. https://doi.org/10.3390/jcm10010087

Formica, V., Lucchetti, J., Doldo, E., Riondino, S., Morelli, C., Argirò, R., Renzi, N., Nitti, D., Nardecchia, A., Dell’Aquila, E., Ferroni, P., Guadagni, F., Palmieri, G., Orlandi, A., & Roselli, M. (2021). Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients—The Importance of Tissue/Plasma Discordant Cases. Journal of Clinical Medicine, 10(1), 87. https://doi.org/10.3390/jcm10010087